Breakout Group #5
Institutional bridge support: How to maintain productive physician-investigators during funding lapses

November 12, 2015
Karen Antman
Don Rockey

Measuring Academic Medicine’s Investment in Medical Research

Bridge Funding Findings
September 11, 2015
About the study

• Goal: to determine the full institutional investment in biomedical research.

• The AAMC partnered with business office and research leaders at US medical schools, and Huron Consulting Group to develop a data collection tool that defines and facilitates consistent reporting across major categories of investment.

• Full report at aamc.org/initiatives/research

• Institutions support $0.53 for every dollar of funded research received.

About the data collection tool

The survey tool supports uniform reporting of:

• Sponsored program direct, indirect and total costs;
• Related institutional direct and indirect costs.

Data collected: institutional 2013 Fiscal Year

Sponsored program investments were also reported by source type:

• Federal-NIH
• Other Federal
• State and Local government
• Industry/Corporate
• Foundation/Not-for-profit
• Incoming subawards and subcontracts
• Other
Characteristics of participating institutions

Total Direct Sponsored Research Expenditures

- More than $150M: 52%
- Less than $150M: 48%

Region

- Northeast: 24%
- South: 33%
- Midwest: 26%
- West: 17%

Public v. Private

- Public: 61%
- Private: 39%

Sponsored Research Expenditures by Sponsor Type

Average in thousands

<table>
<thead>
<tr>
<th>Sponsor Type</th>
<th>Average</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIH</td>
<td>$146,980</td>
</tr>
<tr>
<td>Other Federal</td>
<td>$21,729</td>
</tr>
<tr>
<td>Subcontracts</td>
<td>$23,549</td>
</tr>
<tr>
<td>Foundation/Non-Profit</td>
<td>$20,607</td>
</tr>
<tr>
<td>Industry/Corporate</td>
<td>$17,481</td>
</tr>
<tr>
<td>State &amp; Local Government</td>
<td>$7,423</td>
</tr>
<tr>
<td>Other</td>
<td>$4,093</td>
</tr>
<tr>
<td>Total</td>
<td>$240,024</td>
</tr>
</tbody>
</table>

Totals includes direct and indirect (F&A) expenditures by sponsor type.
Sponsored Research Total Direct Cost

Mean: $190,097,959 (SD $146,752,442)
Mean Public: $187,470,282 (SD $150,397,765)
Mean Private: $194,185,456 (SD $145,098,816)

Institutional Support as a % of Sponsored Programs Expense

Mean: 53% (SD 31%)
Mean Public: 56% (SD 23%)
Mean Private: 45% (SD 18%)
Definition of bridge funding used in study

A structured form of research support, which could include a formalized application for these funds, a defined amount of support, and the timeframe over which the funds may be used.

Bridge funding provides support for researchers who have promising lines of inquiry but due to the highly competitive nature of research funding, have temporarily lost support.
Institutional Research Expenditures by Category

- **Institutions < $150M Sponsored TDC**
  - Dept F&A: 23% 3% 3% 7% 4% 1%
  - F&A Unrecovered: 28% 19% 7%

- **Institutions > $150M Sponsored TDC**
  - Over the salary cap: 22% 5%
  - Start up packages: 5% 3%
  - Bridge Funding: 4%
  - Additional salary: 10%

- **Mandatory/Voluntary Committed Cost Sharing**
- **University Research**
- **Bridge Funding**
- **Additional Salary Support of Research Effort**
- **Unrecovered OR/OSA F&A Subsidy**

Bridge Funding Percentage of Total Institutional Investment

- Public: Mean: 4% (SD 5%)
- Private: Mean: 3% (SD 3%)
- Mean Private: 6% (SD 4%)

© 2015 AAMC. May not be reproduced without permission.
Individual Bridge Awards:
US Medical Schools Reporting Bridge Funding (n=74)*

<table>
<thead>
<tr>
<th>Amount of Bridge Award</th>
<th>Number (%) of Responding Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>$50,000 or less</td>
<td>34 (46%)</td>
</tr>
<tr>
<td>$50,001 - 100,000</td>
<td>25 (34%)</td>
</tr>
<tr>
<td>$100,001 - 150,000</td>
<td>1 (1%)</td>
</tr>
<tr>
<td>$150,001 - 1,000,000</td>
<td>3 (4%)</td>
</tr>
<tr>
<td>No Cap on Amount</td>
<td>7 (9%)</td>
</tr>
</tbody>
</table>

Average Bridge Funding by Research Intensity in $ Millions

<table>
<thead>
<tr>
<th>Institutional Expenditure</th>
<th>Institutions &lt; $150 Million Sponsored TDC</th>
<th>Institutions &gt; $150 Million Sponsored TDC</th>
<th>All Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
<td>Mean</td>
</tr>
<tr>
<td>Bridge Funding</td>
<td>2.8</td>
<td>4.2</td>
<td>5.1</td>
</tr>
<tr>
<td>Total Institutional Expenditures</td>
<td>69</td>
<td>36</td>
<td>149</td>
</tr>
<tr>
<td>Total Sample Size</td>
<td>18</td>
<td>18</td>
<td>20</td>
</tr>
</tbody>
</table>

© 2015 AAMC. May not be reproduced without permission.
Physician-Scientists

• In 2012, physician-scientists comprised 1.5% of the total physician workforce
• In 2002, 14,531 and in 2012, there were 13,717
• During the 5-year period 2008-2012, approximately 8,000 MDs held NIH RPG awards
• This workforce is shrinking, aging and includes a small proportion of women and racial/ethnic minorities

From the Physician-Scientist Workforce Working Group Report, June 2014

Physician-Scientists

• Takes longer than ever to become independent
  – Age at 1st R01 = 44 MD, 45 MD/PhD
• If the average career of a physician-scientist is 30 years, it is estimated that about 1,000 individuals will need to enter the pipeline each year to maintain a steady state (assuming 50% will not succeed)

From the Physician-Scientist Workforce Working Group Report, June 2014
K to R Bridging

- More than 80 percent of K program recipients (1999-2008) have applied for RPGs.
  - Of those who applied, approximately 60% were successful, for an overall K to R rate of 54%.
- In 2012, the award rate for MDs or MD/PhDs with a prior R01 was 23%.
### R to R Transition

- **Renewal of R01 has declined substantially over the last 10 years**

![Graph showing decline in renewal rates](http://loop.nigms.nih.gov/2015/02/examining-the-first-competing-renewal-rates-of-new-nigms-investigators/)

"Examining the First Competing Renewal Rates of New NIGMS Investigators"

---

### R to R Transition – Renewal History

- Those renewing R grants are typically more successful than new investigators, but…

![Bar chart showing renewal history](http://loop.nigms.nih.gov/2015/02/examining-the-first-competing-renewal-rates-of-new-nigms-investigators/)

"Examining the First Competing Renewal Rates of New NIGMS Investigators"
R to R Transition

• Experience helps!

“Examining the First Competing Renewal Rates of New NIGMS Investigators”

Discussion Topics

• What are best practices nationally?
  ➢ Are these adequate?
• Specific programs for the K to R phase?
• What about R to R?
• How does one handle the established investigator who has “run out the string”?
Contents

Executive Summary ........................................................................................................................................... 4
Methodology ...................................................................................................................................................... 5
Results........................................................................................................................................................... 6
  Table 1: Institutional F&A Investment ............................................................................................................ 6
  Table 2: Institutional Salary Expenditures ..................................................................................................... 7
  Figure 1: Bivariate Analysis—Institutional Total Investment versus Sponsored Programs Total Cost .... 8
Conclusion .......................................................................................................................................................... 9
Additional Metrics and Graphs ......................................................................................................................... 9
  Figure 2: Sponsored Programs Expense by Sponsor Type ........................................................................... 9
  Table 3: Sponsored Programs Mean Expense .............................................................................................. 10
  Figure 3: Sponsored Programs Total Direct Cost .......................................................................................... 11
  Figure 4: Total Institutional Investment ........................................................................................................ 11
  Figure 5: Mandatory/Voluntary Committed Cost-Sharing Percentage of Total Institutional Investment ....12
  Figure 6: Over-the-Salary-Cap Cost-Sharing Percentage of Total Institutional Investment .................... 12
  Figure 7: University-Research Percentage of Total Institutional Investment .............................................. 13
  Figure 8: Start-Up–Funding Percentage of Total Institutional Investment ................................................... 13
  Figure 9: Bridge–Funding Percentage of Total Institutional Investment ....................................................... 14
  Figure 10: Cost-Overrun Percentage of Total Institutional Investment ......................................................... 14
  Figure 11: Additional-Research-Salary Percentage of Total Institutional Investment ................................. 15
  Figure 12: Other-Institutional-Research Percentage of Total Institutional Investment ............................... 15
  Figure 13: Unrecovered Organized Research and Other Sponsored Activities
    F&A Subsidies Percentage of Total Institutional Investment ................................................................. 16
  Figure 14: Departmental-Research F&A Expenditures Percentage of Total Institutional Investment ......... 16
  Figure 15: Institutional-Research Expenditures by Category ...................................................................... 17
  Figure 16: Institutional Research as a Percentage of Sponsored Programs Expense ................................ 18
  Figure 17: Institutional-Research Percentage of Total Research .............................................................. 18
  Figure 18: NIH Effective F&A Recovery Rate .............................................................................................. 19
  Figure 19: Other Federal Effective F&A Recovery Rate ............................................................................. 19
  Figure 20: State and Local Government Effective F&A Recovery Rate .................................................... 20
  Figure 21: Industrial/Corporate Effective F&A Recovery Rate ................................................................. 20
  Figure 22: Foundation/Not-for-Profit Effective F&A Recovery Rate .......................................................... 21
  Figure 23: Subaward and Subcontract Effective F&A Recovery Rate ........................................................... 21
  Figure 24: Other-Sponsor Effective F&A Recovery Rate ............................................................................ 22
  Figure 25: Overall Effective F&A Recovery Rate ......................................................................................... 22
Definitions ........................................................................................................................................................ 23
Executive Summary

Medical research has improved the health of Americans, fueled the economy, and spurred innovation. Such advances have been possible because of investments by federal, state, and local government, industry, foundations, and academic institutions. More than half of National Institutes of Health (NIH) extramural funding—roughly $13 billion in FY 2014—supports researchers in the nation’s medical schools and teaching hospitals.

Academic medical centers are committed to preserving the tripartite missions of academic medicine: education, patient care, and research. The flow of revenue and funds for these three enterprises is unique to individual institutions. Data from FY 2013 indicate that grants and contracts account for 26% of the total revenue that supports medical school programs and activities. This proportion is second only to revenue received from clinical operations. To cover both direct and indirect costs, academic medical centers must subsidize these funds with their own investment. The full extent of this investment has not been well characterized—until now.

To measure the comprehensive investment of academic medicine in research, the Association of American Medical Colleges (AAMC) partnered with business office and research leaders at U.S. medical schools and engaged Huron Consulting Group (Huron) to develop a survey tool that allows consistent reporting of the investment in medical research across medical schools. The survey tool provides (1) a measure of the overall institutional investment for every extramural dollar received for research and (2) the distribution of institutional investment across subcategories.

Forty-six institutions collaborated with the AAMC and Huron on this effort. These institutions each received between $26 million and $751 million in external funding (total direct costs, or TDC) for medical research in 2013. The average medical school investment was an additional $0.53 for each dollar of sponsored research received. This accounted for an average investment of $111 million per medical school.


This technical report presents data that supplement results summarized in the AAMC Academic Medicine Investment in Medical Research main report. The Results section here describes details relating to the metrics derived from the survey results, including results that are stratified by public and private institutions and by research intensity. The report also includes an Additional Metrics and Graphs section, with frequency charts showing distributions of the results from the survey, such as sponsored programs expense by sponsor type, institutional investment, and facilities and administrative (F&A) recovery rate by sponsor type.

**Methodology**

On November 1, 2013, the AAMC convened a group of eight principal business officers and four deans of research from 12 accredited U.S. medical schools and representatives from Huron. This group designed the Investment in Research Survey Tool and developed definitions and instructions for the survey instrument. On April 2, 2014, the survey was distributed to a pilot group of 12 institutions represented by the people who were at the November meeting. Eleven institutions responded to the survey by June 26, 2014, and provided additional feedback about the survey instrument and definitions.

On August 1, 2014, the updated survey was distributed to 57 institutions (including the 12 pilot institutions). Responses were received from 46 institutions by November 1, 2014. The overall response rate for all participants was 81%. As survey responses were received, Huron contacted respondents to discuss data accuracy and methods of reporting. Eight institutions reported incomplete data because of limitations in data reporting from their financial systems. Therefore, the information from these institutions could not be included in the reported results.

Institutional-research expenditures were calculated by summing total direct costs of institution-funded research, unrecovered F&A subsidies related to organized research and other sponsored activities, and F&A subsidies related to the institutional subsidy of direct research expenditures.
Results

The primary finding is that the average medical school investment applied to externally supported research programs was $0.53 for each dollar of sponsored research received. This accounted for an average investment of $111 million, with a 95% confidence interval between $90 million and $132 million per medical school.

More than half of the investment, $0.27 for every dollar of sponsored research expended at a medical school, is related to F&A costs of the institution not reimbursed by sponsors (Table 1). Overall, the largest institutional expenditures were incurred to cover unreimbursed F&A costs, with an average of $0.15 going to support unreimbursed indirect costs from extramural funds and $0.12 going to support F&A costs associated with intramural funds provided by the institution. As indicated in Figures 13 and 14 in the Additional Metrics and Graphs section, there was a mean of 31% (range from 2% to 63%) for the unreimbursed organized research and other sponsored activities (OR/OSA) F&A subsidies portion of the total institutional investment, and a mean of 21% (range, 3% to 34%) for the departmental-research F&A expenditures portion of the total institutional investment.

<table>
<thead>
<tr>
<th>Table 1. Institutional F&amp;A Investment</th>
<th>Institutional Expenditures</th>
<th>Total Institutional F&amp;A Expenditures</th>
<th>Total Institutional F&amp;A Expenditures Expressed as Per Dollar of Sponsored Programs Dollars Received</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average</td>
<td>$56,060,001</td>
<td>$0.27</td>
<td></td>
</tr>
<tr>
<td>95% Confidence Interval</td>
<td>± $10,440,571</td>
<td>± $0.04</td>
<td></td>
</tr>
<tr>
<td>Sample Size</td>
<td>38</td>
<td>38</td>
<td></td>
</tr>
</tbody>
</table>
A large portion of the investment, $0.21 for every dollar of sponsored research expended at a medical school, is related to salary costs (Table 2). Additional salary support of the research effort, which is salary that is charged to discretionary-type funding (and not charged to sponsored funds or other specified institutional funding mechanisms), was the largest component of this portion of the investment, averaging $0.09, or 15% of the total institutional investment. As indicated in Figure 11, additional salary support of the research effort had a mean of 15%, with values ranging from 0% to 37% of the total institutional investment.

Start-up funding and bridge funding, which traditionally consist predominantly of salary costs, averaged 9% and 4%, respectively (Figures 8 and 9). Mandatory/voluntary committed and over-the-salary-cap cost sharing each averaged 5% (Figures 5 and 6). Although the mean for over-the-salary-cap cost sharing was 5% of the total institutional investment, one institution reported over-the-salary-cap cost sharing at 30% of their institutional investment (Figure 6). Federal funding made up 89% of this institution’s sponsored-research portfolio, compared with a mean of 70%. Given that salary caps are generally imposed by federal sponsors, this may explain this institution’s high salary-cap cost-sharing investment.

Components of the salary investment are comparable across public and private institutions and research intensity, with the largest variance seen in the additional salary support of the research-effort category (Figure 11). For this component, public institutions averaged $0.11, or 16% of the total investment, while private institutions averaged $0.06, or 12% of the total investment. Institutions with less than $150 million in sponsored-research total direct costs averaged $0.13, or 19% of the total investment, while institutions with more than $150 million in sponsored-research total direct costs averaged $0.06, or 10% of the total investment (Figure 15).

Table 2. Institutional Salary Expenditures*

<table>
<thead>
<tr>
<th>Total Institutional Salary Expenditures</th>
<th>Total Institutional Salary Expenditures Expressed as Per Dollar of Sponsored Programs Dollars Received*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average</td>
<td>$40,257,593</td>
</tr>
<tr>
<td>95% Confidence Interval</td>
<td>± $10,282,462</td>
</tr>
<tr>
<td>Sample Size</td>
<td>30</td>
</tr>
</tbody>
</table>

* Institutional salary expenditures consist of mandatory/voluntary committed cost sharing, over-the-salary-cap cost sharing, start-up funding, bridge funding, and additional salary support of the research effort.
Results were generally comparable for the remaining components of the investment. However, as indicated in Figure 10, cost overruns at one institution made up 19% of its institutional investment—well above the mean of 2%. This institution separately budgets and accounts for cost overruns but does not track many of the other direct institutional investment categories reported in the survey. Therefore, the overall institutional investment may be understated, with cost overruns making up the majority of the direct institutional investment reported.

As Figure 1 indicates, there is a positive relationship between sponsored-research support and institutional investment. This means that as an institution incurs additional sponsored programs expense, additional institutional investment in the research enterprise is needed.
**Conclusion**

There is a positive linear relationship between sponsored programs total cost and institutional total investment (Figure 1). Institutions with less than $150 million in sponsored programs total direct costs spend a proportionally greater percentage of institutional-research expenditures on additional salary support than institutions with more than $150 million in sponsored programs total direct costs (19% versus 10%). The other measured categories are generally comparable across public and private institutions and research intensity. For all survey respondents, the largest proportion of sponsored research is supported by NIH. NIH also provides the largest proportion of support for facilities and administrative (F&A) costs. These results indicate that medical schools make substantial investments in medical research, including unrecovered F&A costs related to sponsored programs, departmental-research F&A, salary support, and additional areas of support.

**Additional Metrics and Graphs**

![Figure 2: Sponsored Programs Expense by Sponsor Type](image-url)
# Table 3: Sponsored Programs Mean Expense

<table>
<thead>
<tr>
<th>Sponsor Type</th>
<th>Institutions &lt; $150 Million Sponsored TDC</th>
<th>Institutions &gt; $150 Million Sponsored TDC</th>
<th>All Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean SD</td>
<td>Mean SD</td>
<td>Mean SD</td>
</tr>
<tr>
<td>NIH</td>
<td>69,046,642 $38,769,163</td>
<td>224,912,972 $107,019,904</td>
<td>146,979,807 $111,990,466</td>
</tr>
<tr>
<td>Other Federal</td>
<td>12,176,792 9,558,089</td>
<td>31,280,337 33,060,627</td>
<td>21,728,565 25,907,514</td>
</tr>
<tr>
<td>State and Local Government</td>
<td>4,738,226 4,999,838</td>
<td>10,236,238 13,530,379</td>
<td>7,423,301 10,363,817</td>
</tr>
<tr>
<td>Industrial/Corporate</td>
<td>6,456,233 4,316,963</td>
<td>28,506,326 32,402,269</td>
<td>17,481,279 25,401,588</td>
</tr>
<tr>
<td>Foundation/Not-for-Profit</td>
<td>9,798,762 9,972,567</td>
<td>31,414,244 19,070,013</td>
<td>20,606,503 18,585,577</td>
</tr>
<tr>
<td>Subaward/Subcontracts</td>
<td>10,753,454 6,201,169</td>
<td>36,345,298 17,066,406</td>
<td>23,549,376 18,126,406</td>
</tr>
<tr>
<td>Other Sponsors</td>
<td>1,134,421 2,619,116</td>
<td>7,052,191 11,964,012</td>
<td>4,093,306 9,063,000</td>
</tr>
<tr>
<td><strong>Total Sponsored</strong></td>
<td><strong>$112,061,974</strong> $48,971,782</td>
<td><strong>$362,422,634</strong> $183,463,467</td>
<td><strong>$240,024,089</strong> <strong>$184,370,209</strong></td>
</tr>
<tr>
<td><strong>Total Sample Size</strong></td>
<td>22 22 23 23 45 45</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Total Direct Cost</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>NIH</td>
<td>50,078,436 $26,095,241</td>
<td>165,096,749 $79,103,582</td>
<td>107,587,592 $82,295,348</td>
</tr>
<tr>
<td>Other Federal</td>
<td>9,871,632 7,961,622</td>
<td>25,321,363 27,776,660</td>
<td>17,596,497 21,642,829</td>
</tr>
<tr>
<td>State and Local Government</td>
<td>4,159,788 4,567,577</td>
<td>8,984,035 11,562,916</td>
<td>6,515,816 8,947,189</td>
</tr>
<tr>
<td>Industrial/Corporate</td>
<td>5,159,791 3,652,285</td>
<td>22,833,992 28,764,381</td>
<td>13,996,891 22,128,773</td>
</tr>
<tr>
<td>Foundation/Not-for-Profit</td>
<td>9,209,487 9,878,395</td>
<td>28,869,499 17,520,154</td>
<td>19,039,493 17,210,158</td>
</tr>
<tr>
<td>Subaward/Subcontracts</td>
<td>7,992,554 4,709,609</td>
<td>26,248,003 12,458,314</td>
<td>17,120,279 13,110,269</td>
</tr>
<tr>
<td>Other Sponsors</td>
<td>954,776 2,118,271</td>
<td>5,707,971 10,033,724</td>
<td>3,331,373 7,558,974</td>
</tr>
<tr>
<td><strong>Total Sponsored</strong></td>
<td><strong>$85,920,277</strong> $35,715,704</td>
<td><strong>$285,594,167</strong> <strong>$145,170,116</strong></td>
<td><strong>$190,097,959</strong> <strong>$146,752,442</strong></td>
</tr>
<tr>
<td><strong>Total Sample Size</strong></td>
<td>22 22 24 24 46 46</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>F&amp;A Expenditures</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>NIH</td>
<td>18,968,206 $13,562,866</td>
<td>59,816,223 $28,610,148</td>
<td>39,392,214 $30,271,021</td>
</tr>
<tr>
<td>Other Federal</td>
<td>2,305,160 1,887,660</td>
<td>5,958,974 5,486,581</td>
<td>4,132,067 4,454,363</td>
</tr>
<tr>
<td>State and Local Government</td>
<td>578,437 1,044,827</td>
<td>1,252,203 2,382,339</td>
<td>907,486 1,834,284</td>
</tr>
<tr>
<td>Industrial/Corporate</td>
<td>1,296,442 823,708</td>
<td>5,672,334 4,147,546</td>
<td>3,484,388 3,690,655</td>
</tr>
<tr>
<td>Foundation/Not-for-Profit</td>
<td>589,274 421,910</td>
<td>2,544,745 1,797,002</td>
<td>1,567,010 1,624,933</td>
</tr>
<tr>
<td>Subaward/Subcontracts</td>
<td>2,760,900 1,866,391</td>
<td>10,097,294 5,042,733</td>
<td>6,429,097 5,280,866</td>
</tr>
<tr>
<td>Other Sponsors</td>
<td>128,081 484,539</td>
<td>979,158 1,835,107</td>
<td>563,076 1,407,469</td>
</tr>
<tr>
<td><strong>Total Sponsored</strong></td>
<td><strong>$26,141,696</strong> $15,686,269</td>
<td><strong>$84,429,554</strong> <strong>$41,728,402</strong></td>
<td><strong>$55,933,268</strong> <strong>$43,084,921</strong></td>
</tr>
<tr>
<td><strong>Total Sample Size</strong></td>
<td>22 22 23 23 45 45</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: Total sponsored expenditures may be different from the total of the expenditures per category because the sample size may be different between categories.
Figure 3: Sponsored Programs Total Direct Cost

Mean: $190,097,959 (SD $146,752,442)
Mean Public: $187,470,282 (SD $150,397,765)
Mean Private: $194,185,456 (SD $145,098,816)

Figure 4: Total Institutional Investment

Mean: $111,151,553 (SD $66,500,737)
Mean Public: $115,495,374 (SD $65,211,745)
Mean Private: $104,491,029 (SD $70,188,968)

Note: Total Investment Amount = Institutional Total Direct Costs + Unrecovered OR/OSA F&A Subsidies + Departmental-Research F&A Expenditures
Figure 5: Mandatory/Voluntary Committed Cost-Sharing Percentage of Total Institutional Investment

- Mean: 5% (SD 3%)
- Mean Public: 4% (SD 2%)
- Mean Private: 5% (SD 5%)

Note:
Institutional Total Direct Costs + Unrecovered OR/OSA F&A Subsidies + Departmental-Research F&A Expenditures

Figure 6: Over-the-Salary-Cap Cost-Sharing Percentage of Total Institutional Investment

- Mean: 5% (SD 6%)
- Mean Public: 3% (SD 2%)
- Mean Private: 8% (SD 8%)

Note:
Institutional Total Direct Costs + Unrecovered OR/OSA F&A Subsidies + Departmental-Research F&A Expenditures
Figure 7: University-Research Percentage of Total Institutional Investment

Mean: 3% (SD 6%)
Mean Public: 2% (SD 3%)
Mean Private: 5% (SD 8%)

Public
Private
Mean

Figure 8: Start-Up–Funding Percentage of Total Institutional Investment

Mean: 9% (SD 6%)
Mean Public: 7% (SD 4%)
Mean Private: 12% (SD 8%)

Public
Private
Mean
Figure 9: Bridge-Funding Percentage of Total Institutional Investment

- **Mean: 4% (SD 5%)**
- Mean Public: 3% (SD 5%)
- Mean Private: 6% (SD 4%)

Note: Institutional Total Direct Costs + Unrecovered OR/OSA F&A Subsidies + Departmental-Research F&A Expenditures

Figure 10: Cost-Overrun Percentage of Total Institutional Investment

- **Mean: 2% (SD 4%)**
- Mean Public: 3% (SD 5%)
- Mean Private: 1% (SD 1%)
**Figure 11: Additional-Research-Salary Percentage of Total Institutional Investment**

Mean: 15% (SD 11%)
Mean Public: 16% (SD 12%)
Mean Private: 12% (SD 7%)

- **Public**
- **Private**
- **Mean**

Note: Additional-Research-Salary Total Direct Costs = Institutional Total Direct Costs + Unrecovered OR/OSA F&A Subsidies + Departmental-Research F&A Expenditures

**Figure 12: Other-Institutional-Research Percentage of Total Institutional Investment**

Mean: 8% (SD 6%)
Mean Public: 10% (SD 7%)
Mean Private: 5% (SD 5%)

- **Public**
- **Private**
- **Mean**

Note: Other-Institutional-Research Total Direct Costs = Institutional Total Direct Costs + Unrecovered OR/OSA F&A Subsidies + Departmental-Research F&A Expenditures
**Figure 13: Unrecovered Organized Research and Other Sponsored Activities F&A Subsidies Percentage of Total Institutional Investment**

- **Mean:** 31% (SD 15%)
- **Mean Public:** 31% (SD 17%)
- **Mean Private:** 31% (SD 13%)

Note: Institutional Total Direct Costs + Unrecovered OR/OSA F&A Subsidies + Departmental-Research F&A Expenditures

**Figure 14: Departmental-Research F&A Expenditures Percentage of Total Institutional Investment**

- **Mean:** 21% (SD 7%)
- **Mean Public:** 21% (SD 6%)
- **Mean Private:** 20% (SD 7%)

Note: Institutional Total Direct Costs + Unrecovered OR/OSA F&A Subsidies + Departmental-Research F&A Expenditures
### Figure 15: Institutional-Research Expenditures by Category

<table>
<thead>
<tr>
<th>Institutional Expenditure Category</th>
<th>Institutions &lt; $150 Million Sponsored TDC</th>
<th>Institutions &gt; $150 Million Sponsored TDC</th>
<th>All Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean</td>
<td>Mean</td>
<td>Mean</td>
<td></td>
</tr>
<tr>
<td>SD</td>
<td>Mean</td>
<td>Mean</td>
<td></td>
</tr>
<tr>
<td>SD</td>
<td>Mean</td>
<td>Mean</td>
<td></td>
</tr>
<tr>
<td>Mandatory/Voluntary Committed Cost Sharing</td>
<td>$2,231,102</td>
<td>$7,147,669</td>
<td>$4,878,484</td>
</tr>
<tr>
<td>Over-the-Salary-Cap Cost Sharing</td>
<td>1,913,608</td>
<td>7,733,679</td>
<td>5,114,647</td>
</tr>
<tr>
<td>University Research</td>
<td>2,210,684</td>
<td>4,251,558</td>
<td>3,258,701</td>
</tr>
<tr>
<td>Start-up Packages</td>
<td>4,965,460</td>
<td>14,660,198</td>
<td>9,681,819</td>
</tr>
<tr>
<td>Bridge Funding</td>
<td>2,803,434</td>
<td>5,137,115</td>
<td>4,001,811</td>
</tr>
<tr>
<td>Cost Overruns</td>
<td>907,487</td>
<td>1,763,152</td>
<td>1,410,819</td>
</tr>
<tr>
<td>Additional Salary Support of Research Effort</td>
<td>13,626,422</td>
<td>18,459,411</td>
<td>14,942,281</td>
</tr>
<tr>
<td>Other Institutionally Funded Research</td>
<td>5,095,569</td>
<td>9,394,742</td>
<td>8,079,128</td>
</tr>
<tr>
<td>Unrecovered OR/OSA F&amp;A Subsidies</td>
<td>19,586,549</td>
<td>25,663,843</td>
<td>31,819,883</td>
</tr>
<tr>
<td>Departmental Research F&amp;A Expenditures</td>
<td>15,558,780</td>
<td>20,891,879</td>
<td>24,240,118</td>
</tr>
<tr>
<td>Total Institutional Expenditures</td>
<td>$69,237,092</td>
<td>$148,874,569</td>
<td>$111,151,553</td>
</tr>
<tr>
<td>Total Sample Size</td>
<td>18</td>
<td>20</td>
<td>38</td>
</tr>
</tbody>
</table>

Note: Total institutional expenditures may be different from the total of the expenditures per category because the sample size may be different between categories.
Figure 16: Institutional Research as a Percentage of Sponsored Programs Expense

Mean: 53% (SD 21%)
Mean Public: 58% (SD 23%)
Mean Private: 45% (SD 18%)

Note:
Institutional Total Direct Costs + Unrecovered OR/OSA F&A Subsidies + Departmental-Research F&A Expenditures
Sponsored Programs Total Direct Costs + Sponsored Programs F&A Expenditures

Figure 17: Institutional-Research Percentage of Total Research

Mean: 33% (SD 9%)
Mean Public: 35% (SD 9%)
Mean Private: 30% (SD 8%)

Note:
Institutional Total Direct Costs + Unrecovered OR/OSA F&A Subsidies + Departmental-Research F&A Expenditures
Sponsored Programs Total Direct Costs + Sponsored Programs F&A Expenditures +
Institutional Total Direct Costs + Unrecovered OR/OSA F&A Subsidies + Departmental-Research F&A Expenditures
Figure 18: NIH Effective F&A Recovery Rate

Mean: 46% (SD 6%)
Mean Public: 45% (SD 4%)
Mean Private: 46% (SD 9%)

Note: NIH F&A Expenditures
NIH Modified Total Direct Costs

Figure 19: Other Federal Effective F&A Recovery Rate

Mean: 35% (SD 13%)
Mean Public: 30% (SD 12%)
Mean Private: 40% (SD 12%)

Note: Other Federal F&A Expenditures
Other Federal Modified Total Direct Costs
Figure 20: State and Local Government Effective F&A Recovery Rate

Mean: 13% (SD 12%)
Mean Public: 12% (SD 12%)
Mean Private: 15% (SD 12%)

Public
Private
Mean

Note:
State and Local Government F&A Expenditures
State and Local Government Modified Total Direct Costs

Figure 21: Industrial/Corporate Effective F&A Recovery Rate

Mean: 31% (SD 12%)
Mean Public: 30% (SD 9%)
Mean Private: 33% (SD 15%)

Public
Private
Mean

Note:
Industrial/Corporate F&A Expenditures
Industrial/Corporate Modified Total Direct Costs
Figure 22: Foundation/Not-for-Profit Effective F&A Recovery Rate

Mean: 9% (SD 4%)
Mean Public: 9% (SD 5%)
Mean Private: 10% (SD 4%)

Public  Private  Mean

Note: Foundation/Not-for-Profit F&A Expenditures
Foundation/Not-for-Profit Modified Total Direct Costs

Figure 23: Subaward and Subcontract Effective F&A Recovery Rate

Mean: 40% (SD 11%)
Mean Public: 40% (SD 8%)
Mean Private: 42% (SD 15%)

Public  Private  Mean

Note: Subaward and Subcontract F&A Expenditures
Subaward and Subcontract Modified Total Direct Costs
**Figure 24: Other-Sponsor Effective F&A Recovery Rate**

Mean: 12% (SD 11%)
Mean Public: 8% (SD 8%)
Mean Private: 19% (SD 11%)

**Figure 25: Overall Effective F&A Recovery Rate**

Mean: 37% (SD 8%)
Mean Public: 35% (SD 6%)
Mean Private: 40% (SD 9%)
DEFINITIONS

**additional salary support of research effort.** Additional direct-cost salary expenditures from institutional accounts used in support of internally funded research efforts.

**bridge funding.** A structured form of research support, which could include a formalized application for these funds, a defined amount of support, and the timeframe over which the funds may be used. Bridge funding provides support for researchers who have promising lines of inquiry but due to the highly competitive nature of research funding, have temporarily lost support.

**cost sharing (mandatory and voluntary committed).** Direct-cost expenditures associated with cost sharing required by the terms of the project (mandatory) and cost sharing that is not required but is documented and quantified in the proposal and becomes mandatory when the proposal is accepted (voluntary committed).

**departmental-research F&A expenditures.** Facilities and administrative (F&A) expenditures related to the research classified as departmental research reported on the survey. These departmental-research expenditures include start-up packages, bridge funding, additional salary support for research effort, and other institutionally funded research.

**facilities and administrative (F&A), or indirect, costs.** Costs that are not directly related to an individual research project but are essential to support the research endeavor. These F&A charges include costs of buildings (operations, maintenance, and depreciation), equipment depreciation, information systems, environmental health and safety, and grant management and other support costs.

**institutional-research expenditures.** Calculated by adding institution-funded-research total direct cost (TDC), unrecovered F&A subsidies related to organized research and other sponsored activities, and additional F&A subsidies related to the institutional subsidy of direct research expenditures.

**organized research (OR).** All research and development activities of an institution that are separately budgeted and accounted for. Includes sponsored research, which is sponsored by federal and nonfederal agencies and organizations, as well as university research, which is separately budgeted and accounted for by the institution under an internal application of institutional funds.

**other institutionally funded research.** Institutional direct-cost research expenditures that have not been reported elsewhere on the survey. May include specialized service facility (SSF) and recharge-center subsidies, costs of operating core research facilities, and unreimbursed graduate student stipends or tuition payments.
other sponsored activities (OSA). Programs and projects financed by federal and nonfederal agencies and organizations that involve the performance of work other than instruction and organized research. Examples of such programs and projects are health service projects and community service programs.

over-the-salary-cap cost share. Direct-cost expenditures associated with cost sharing that occurred due to exceeding sponsor-imposed salary caps, such as the National Institutes of Health (NIH) salary cap, on all sponsored programs types.

overruns. Direct-cost expenditures from institutional accounts used to fund cost overruns on sponsored programs as a result of overspending on individual awards. They include expenditures where funds have been moved during the current year from a sponsored account to an institutionally funded account.

sponsored programs expenditures. Calculated by adding sponsored programs TDC and sponsored programs F&A expenditures.

start-up packages. Direct-cost expenditures from institutional funds associated with recruiting or attracting new researchers to the institution, including start-up costs.

university research. Direct-cost expenditures associated with activities that meet the Office of Management of Budget (OMB) uniform guidance definition of university research: all research and development activities that are separately budgeted and accounted for by the institution under an internal application of institutional funds. These funds are typically awarded through an internal proposal submission and evaluation process.

unrecovered OR/OSA F&A subsidies. The gap between the F&A expenditures in support of sponsored programs at an institution and the amount reimbursed by sponsors.
An Assessment of Bridge Funding in U.S. Medical Schools

New discoveries and medical breakthroughs from biomedical research depend on sustained support from the federal government or other external sources. In a fiscal environment where the National Institutes of Health (NIH) budget has fallen by close to 20 percent after inflation, competition for dwindling dollars in federal grants has increased markedly.\(^1\) Some of the most successful career investigators with highly rated peer-reviewed projects have experienced sudden interruptions in funding, as success rates for research project grant applications and funding have declined.\(^2\) In addition, the number of investigators experiencing an interruption or termination in their research funding is expected to increase, as further budget cuts for funding of biomedical research are likely.\(^3\) Whether an institution’s research program conducts $600 million or $60 million in NIH-sponsored research, the increased risk in interruption or cessation of competitive research projects can devastate established programs, leading to dislocation of faculty, trainees, and staff, and a delay or loss of medical breakthroughs.

Bridge funding is one mechanism whereby academic institutions can provide support during lapses in federal funding to investigators with high-quality research projects who are likely to regain funding in the near future. While bridge funds are not intended to fully replace or offset external sources, they can help in the short run to sustain some elements of a research project and prevent disruption and loss of momentum that could take decades to regain.

The U.S. LCME-accredited medical schools perform approximately 55 percent of all NIH extramural research, including nearly 28,000 research project grants and more than $12 billion annually.\(^4\) This Analysis in Brief explores how these institutions bridge investigators who experience an interruption in funding. Information about the scope and variability of bridge funding policies designed to address these risks across medical centers may assist deans and other leaders of biomedical research programs in determining whether to implement or revise bridge funding programs at their own institutions.

Methodology

The data in this AIB come from two sources. First, in 2012, we fielded an email survey to research deans who are members of the AAMC Group on Research Advancement and Development (123 U.S. medical schools).\(^5\) The survey elicited information about whether an institution has a bridge funding policy, what the criteria for receiving bridge funds are, what the amounts and limits of bridge awards are, and whether the school limits the number of bridge funding awards. The survey also included an open-ended question regarding other aspects of the institutions’ bridge funding policies that the research deans considered notable.

Second, to analyze the details of these programs further, we reviewed the public Web sites of the 49 institutions that post bridge funding policies on publicly accessible Web sites.\(^6\) Each site was examined at length for specific details complementing general information sought in the survey questions: for example, if bridge policies limit awards to an individual principal investigator (PI) or to an individual research project, or if bridge awards are split between institutional and departmental funds.

We collected survey information from 74 of 123 institutions (60 percent response rate), and reviewed the 49 Web sites where current policies were posted.

Results

Sixty-seven (91 percent) of the 74 institutions that responded to the survey had a formal bridge funding policy.\(^7\) In 59 (80 percent) of the participating institutions, bridge award amounts were limited to $100,000 or less (see Figure). Respondents indicated other ways that institutions limit awards (e.g., per PI or per project). Survey results suggest that three main criteria are used to assess eligibility for bridge funding: the scientific merit of the project (determined by peer review score and/or an institutional award committee), the track record of the principal investigator, and financial considerations such as the need to retain key research support personnel.

---

1. http://.nihrecord.od.nih.gov/newsletters/2012/07_06_2012/story1.html
2. Initial overall success rates of NIH funding across all institutes for competing continuation of research project grants have declined from 51 to 32 percent (in 2002 and 2011, respectively); for competing continuation research project grant applications resubmitted after an initial rejection, the success rate has declined from 53 to 45 percent during the same time period. See: http://report.nih.gov/success_rates/index.aspx (Table 210)
5. 5GRAND provides a forum for sharing information on issues guiding research at medical schools and teaching hospitals. At the time of the survey, 123 AAMC-member medical schools had designated representatives to GRAND.
6. Forty-two of these institutions responded to the email survey confirming that the posted policies were current. Seven institutions did not respond, but given the prominence of these sites on publicly available Web pages, they were also presumed to be current.
7. We refer to bridge funding “policies” generally. Some respondents also refer variously to bridge funding programs or guidelines. Bridge funding policies, programs, or guidelines are mainly intended for full-time tenured, tenure track, or research track faculty who are PIs on national extramural grants with an active submission of an external grant application.
Of the 49 institutions posting policies on their Web sites, 22 report limits on how often a single PI can receive a bridge award. The period of eligibility ranged from every 12 to 18 months (12 institutions), to every three to five years (six institutions), to one award per career (four institutions). Institutions also place limits on what aspects of a project bridge funds will cover. Thirty-two allow bridge funds to be used for research personnel, supplies, and animal care, while only 17 allow monies to be used for the salary of the PI.

While our initial questions asked about the monetary amount or limit of awards, it became clear that the contribution may be divided between the institution and individual departments. Twenty-seven institutions require the PI’s department to provide matching funds to those given by the institution. Two of these institutions require bridge funding recipients to acknowledge and credit the institution for its support in any publication resulting from the supported research. All institutions require that bridge funding cease as soon as sponsored funding becomes available, and unused funds returned.  

Some responses and Web sites offer information regarding the actual success of these programs in sustaining ongoing research. Three institutions reported total dollar investments in bridge programs ($1.28 million, $2.2 million, and $8 million, respectively) and their calculations of the total dollar amount for research project grants that were externally funded after the investigators received the bridge funding ($14.6 million, $30.7 million, and $78 million, respectively). Of five institutions reporting overall success rates for their respective bridge funding programs, an average of 63 percent of bridged investigators subsequently received extramural funding for the most recent year available (2010 or 2011).

Discussion
Medical schools consider bridge support an important strategy to help sustain research programs, as demonstrated by the presence of a formal bridge funding policy or program at most participating institutions. However, even vigorous bridge funding programs cannot adequately make up for the dwindling NIH budget in sustaining biomedical research. Moreover, deeper cuts to all federal domestic discretionary spending, including NIH’s budget, are widely anticipated. These cuts would likely occur during other proposed reductions that would affect clinical revenue—a major source of institutional funds available for bridge programs. The prospect of decreases in funding for graduate medical education, disproportionate share payments, and uncompensated care reimbursements, will not only weaken these important, socially beneficial programs, but also will imperil the capacity of academic medical centers to provide bridge funds for temporarily maintaining research programs.

These budgetary constraints place increasing pressure on institutions to make difficult choices about how they allocate funds to support research. Bridge funding can provide one testable strategy for institutions to invest in researchers with meritorious track records. It is a mechanism through which funds go directly to a PI to provide interim support for a high-quality research program with some degree of flexibility until grant funding is regained. While bridge funding only provides modest and temporary support for otherwise competitive research projects, it could save valuable research programs. In this analysis, only a few institutions spontaneously reported the success of their programs in bridging gaps between periods of external grant support; however, their results suggest that bridge funding may be a cost-effective mechanism to help sustain research, if only as a temporary lifeline. In these fiscally perilous times, where institutions are having to make difficult choices about allocations of funds, evaluation of the bridge funding program to determine the return on investment may offer guidance in future investments.

Authors:
Stephen Heining, M.A., Director, Science Policy, sheining@aamc.org
Irena Tartakovsky, M.D., M.S., Sr. Science Policy Analyst, itartakovsky@aamc.org
Ann Bonham, Ph.D., Chief Scientific Officer, abonham@aamc.org

The authors thank Pamela Mercer for her extensive assistance in undertaking this analysis.

Association of American Medical Colleges
2450 N Street, N.W.
Washington, D.C. 20037-1127
analysis@aamc.org
www.aamc.org/data/aib